Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSGALNACT1 | Q8TDX6 | 15/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297268 | 0.90 | CSGALNACT1 (0.61) | CSGALNACT1KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL2293643 | 0.86 | SMN1; SMN2 (0.58) | CSGALNACT1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL2294670 | 0.83 | HDAC3 (0.47) | KDM4ESMN1; SMN2MAPTLMNAHDAC8 | |
| SCHEMBL19747112 | 0.83 | SMN1; SMN2 (0.52) | KDM4ESMN1; SMN2MAPTHDAC8 | |
| SCHEMBL17652552 | 0.80 | MAPT (0.53) | CSGALNACT1KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL17652621 | 0.80 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2LMNAHDAC8 | |
| SCHEMBL2296671 | 0.77 | CSGALNACT1 (0.60) | CSGALNACT1KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL17652544 | 0.76 | MAPT (0.56) | CSGALNACT1KDM4ESMN1; SMN2MAPTLMNA | |
| SCHEMBL17652574 | 0.76 | SMN1; SMN2 (0.54) | KDM4ESMN1; SMN2MAPT | |
| SCHEMBL2298959 | 0.75 | MEN1 (0.53) | CSGALNACT1KDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | claimed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | claimed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | claimed |
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | disclosed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | disclosed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | CSGALNACT1 455/4885KDM4E 4272/4885SMN1; SMN2 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.